I read an update from fund manager DMX saying they were asking management to divest Sofihub because it was a drain on cash flow. I do agree Hazza that the two remaining businesses are pretty small and have limited growth prospects (niche area as you say) as there are only so many pharmacists out there who are accredited to do these medication reviews. The admin costs of being asx listed are going to mean limited profits flow to shareholders and im struggling to see how this scales to a larger company.
I read an update from fund manager DMX saying they were asking...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
